レプチンとポンチンは,ゼブラフィッシュの胚における心臓の成長を敵対的に調節する
Wolfgang Rottbauer1, Andrew J Saurin, Heiko Lickert
1Cardiovascular Research Center, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.
Cell
|December 5, 2002
まとめ
ゼブラフィッシュの突然変異は,タンパク質複合体の構成要素であるレプチンを過度に活性化することによって,胚の心臓を拡大させます. これは,レプチン/ポントンの比率がベータ-カタニン経路を通じて心臓の成長を調節することを示唆しています.
科学分野:
- 発達生物学 発達生物学について
- 心血管科学の研究について
- 遺伝学 遺伝学とは
背景:
- 臓器の大きさの調節は極めて重要だが,よく理解されていない.
- 胚の心臓の発達には,細胞増殖の正確な制御が伴う.
研究 の 目的:
- ゼブラフィッシュの胚性心臓の大きさを制御する遺伝的メカニズムを調査するために.
- 心臓の多発症に関与する遺伝子や経路を特定する.
主な方法:
- "liebeskummer" (リク) ゼブラフィッシュの変異の分離と特徴付け.
- レプチンタンパク質の機能とATPアゼの活性に関する分析.
- 心臓発育におけるβ-カテニンとポンティンの役割を調査する.
主要な成果:
- ゼブラフィッシュのリック突然変異は,胚性心臓の多重可塑性につながる.
- この変異は,レプチン複合体のATPアゼ活性を増大させ,心筋細胞の増殖を引き起こします.
- レプチン/ポントンの比率とベータ-カテニンの経路は,心臓の成長の調節に極めて重要です.
結論:
- レプチン/ポントンの比率は,胚性心臓の成長の重要な調節因子である.
- この比率の調節不良は,リク変異で見られるように,心臓の多発症を引き起こす.
- この発見は,レプチン/ポンチン媒介の心臓発育におけるβ-カタニン経路を意味している.
関連する概念動画
01:30Combined Effects of Drugs: Antagonism
11.8K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.8K
01:17Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K